Chongqing Peg-bio Biopharm Co., Ltd.
Clinical trials sponsored by Chongqing Peg-bio Biopharm Co., Ltd., explained in plain language.
-
New shot could cut IV feeding for short bowel patients
Disease control Recruiting nowThis study tests a drug called PJ009 in people aged 14 and older with short bowel syndrome who rely on IV nutrition. The goal is to see if daily shots can safely reduce the amount of IV nutrition they need. Participants will receive either PJ009 or a placebo for 24 weeks, then al…
Phase: PHASE3 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
One-Shot platelet boost: new drug could cut bleeding risk in liver patients
Disease control Recruiting nowThis study tests a single shot of PN20, a lab-made protein, to safely raise platelet counts in adults with chronic liver disease who have low platelets and need a planned procedure. About 54 participants will get either PN20 or a placebo before their procedure. The goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New shot aims to boost platelets in rare bleeding disorder
Disease control Recruiting nowThis early study tests a new drug called PN20 in 12 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive one injection and are monitored for safety and platelet count changes. The go…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC